Saudi Arabia Mostafa Abdelrahman, General Manager of Lilly Saudi Arabia, discusses the company’s evolution from medicine supplier to healthcare partner, supporting Vision 2030 through innovation, public-private collaboration and localisation. He highlights advances in obesity, Alzheimer’s disease and oncology, alongside technology transfer, clinical research and talent development, while outlining priorities to expand patient…
USA Amy Adams stepped into the role of director of the National Institute of Neurological Disorders and Stroke (NINDS) at the beginning of the year after more than two decades within the National Institutes of Health (NIH) and serving as the institute’s acting deputy director. As a lifelong researcher, Dr Adams…
Hong Kong Roche Diagnostics Hong Kong is entering a defining phase as the city accelerates its shift toward primary care, early detection and data-driven decision making. In this interview, General Manager Ronald Lo reflects on eighteen months of strategic progress, from expanding point-of-care testing and preparing breakthrough Alzheimer’s‑related biomarkers to shaping regulatory…
France France’s patient advocacy network is one of Europe’s most well-developed and formalised. Patient advocacy groups – including the three featured below – fill in research, care, and support gaps left by private industry and the state while elevating the concerns of the most important people within healthcare: patients and their…
France This conversation with Bruno Dubois offers a clear, experience-driven perspective on how Alzheimer’s disease is being redefined, from diagnosis and biomarkers to prevention and early intervention. Drawing on decades at the forefront of neurology, he challenges simplified biological definitions, explains why risk must be stratified with rigour, and outlines a…
Brazil Rogerio Frabetti, General Manager of Biogen Brazil discusses the organisation’s strategic transformation as it expands beyond its neuroscience heritage into immunology whilst maintaining leadership in rare diseases. He articulates Brazil’s elevation to a top-tier global market, outlines ambitious growth trajectories in Alzheimer’s disease and lupus, and addresses the complexities of…
France France Alzheimer’s Joel Jaouen and Benoit Durand articulate a comprehensive strategic framework for addressing one of Europe’s most pressing healthcare challenges. With four decades of operational excellence, the organisation has evolved from a grassroots family initiative into France’s premier associative research funder, developing sophisticated care pathways whilst advocating for systemic…
France Alexis Genin, CEO of Brain & Mind, discusses the strategic vision behind France’s first national hub for neuroscience product development. Established to overcome the fragmented landscape in neuroscience innovation, Brain & Mind unites over 40 partners across industry, research, and investment. Under Genin’s leadership, the organization has focused on closing…
USA What if ageing itself, not just individual diseases, was the root cause of the most devastating conditions we face? That question has shaped the career of Dr. Joshua Hare, a practising cardiologist and biotech founder who is betting on stem cell therapy to shift how we treat age-related illnesses. Dr.…
Global Alzheimer’s Disease takes a heavy toll; not just on patients and caregivers, but on society as a whole. As populations age, this complex and often-stigmatised condition is becoming harder to ignore. Despite recent breakthroughs, we are still far from having the right tools: better diagnostics, effective treatments, and smarter healthcare…
Denmark Neuroscience is once again at the forefront of medical innovation, and Lundbeck is seizing the moment to redefine its future. In this wide-ranging conversation, President & CEO Charl van Zyl outlines how the company is evolving from a heritage-rich organisation into a focused, performance-driven innovator with a maturing pipeline and…
Global As neuroscience reclaims a place at the top table of pharmaceutical innovation, Bristol Myers Squibb (BMS) is quietly reshaping its presence in the field. Spearheaded by its Neuroscience Thematic Research Center, the company is pursuing a dual mandate: to slow the progression of diseases like Alzheimer’s while also addressing their…
See our Cookie Privacy Policy Here
